Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis

BJU International

Volumn 86, Issue 1, 2000, Pages 80-86

  Jones, A ^a,b,c,d   Fujiyama, C ^a,c   Turner, K ^a,b,c   Fuggle, S ^c   Cranston, D ^b   Turley, H ^a   Valtola, R ^e   Bicknell, R ^a   Harris, A L ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Battle Hospital   (United Kingdom)

^e NONE

Author keywords

Angiogenesis; Microvascular density; Prognosis; Testis tumours; Thymidine phosphorylase; VEGF

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; MESSENGER RNA; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; GERM CELL TUMOR; HISTOGENESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH VESSEL; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; SEMINOMA; TESTIS TERATOMA;

EID: 0033918368     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.2000.00660.x     Document Type: Article

References (39)

1. 1 Folkman J. Tumour angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 82-6
2. 2 Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74: 762-6
3. 3 Gasparini G, Harris AL. Clinical importance of the determination of tumour angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13: 765-82
4. 4 Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-9
5. 5 Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Path 1995; 146: 1029-39
6. 6 Ferrara N, Davis-Smyth TD. The biology of vascular endothelial growth factor. Endocr Rev 1997; 10: 4-25
7. 7 Folkman J. What is the role of thymidine phosphorylase in tumour angiogenesis? J Natl Cancer Inst 1996; 88: 1091-2
8. 8 Crew JP, O'Brien T, Bradburn M, Fuggle S, Cranston D, Harris AL. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57: 5281-5
9. 9 O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995; 55: 510-3
10. 10 Koukourakis MI, Giatromanolaki A, Kakolyris S et al. Different patterns of stromal and cancer cell thymidine phosphorylase activity in non small cell lung cancer: impact on tumour neoangiogenesis and survival. Br J Cancer 1998; 77: 1696-703
11. 11 Takebayashi Y, Akiyama S-I, Akiba S et al. Clinicopathological and prognostic significance of an angiogenic factor, thymidine phosphorylase in human colorectal carcinoma. J Natl Cancer Inst 1996; 88: 1110-7
12. 12 Cullen MH, Stenning SP, Parkinson MC et al. Short-course adjuvant chemotherapy in high risk stage 1 non seminomatous germ cell tumours of the testis: a Medical Research Council report. J Clin Oncol 1996; 14: 1106-13
13. 13 Fossa SD, Horwich A, Russell JM, Roberts JP, Jakes R, Stenning. S. Optimal field size in adjuvant radiotherapy (XRT) of stage 1 seminoma - a randomised trial. Proc ASCO 1996; 15: 239
14. 14 Horwich A, Alsanjari NA, 'Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage 1 testicular seminoma. Br J Cancer 1992; 65: 775-8
15. 15 Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance for stage 1 testicular teratoma. J Clin Oncol 1992; 10: 1762-8
16. 16 Freedman LS, Jones WG, Peckham MJ et al. Histopathology in the prediction of relapse of patients with stage 1 testicular teratoma treated by orchidectomy alone. Lancet 1987; 8: 294-8
17. 17 Campbell SC. Advances in angiogenesis research: Relevance to urological oncology. J Ural 1997; 158: 1663-74
18. 18 Jones A, Fujiyama C. Angiogenesis in urological malignancy. BJU Int 1999; 83: 535-56
19. 19 Joukov V, Pajusola K, Kaipainen A et al. A novel vascular endothelial growth-factor, VEGF-C, is a ligand for the flt-4 (VEGFR-3) and kdr (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 290-8
20. 20 Turley H, Scott PAE, Watts VM, Bicknell R, Harris AL, Gatter KC. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 1998; 186: 313-8
21. 21 O'Brien TS, Fox SB, Dickinson AJ et al. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 1996; 56: 4799-804
22. 22 Fox S, Moghaddam A, Westwood M et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol 1995; 176: 183-90
23. 23 Parums DV, Cordell JL, Micklem K, Heryat AR, Gatter KC, Mason DV. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990; 43: 752-7
24. 24 Jussila L, Valtola R, Partanen TA et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res 1998; 58: 1599-604
25. 25 Jones A, Harris AL. New developments in angiogenesis: a major mechanism for tumour growth and target for therapy. Cancer Journal from Sci Am 1998; 4: 209-17
26. 26 Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4
27. 27 O'Reilly M, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85
28. 28 Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996; 56: 393-401
29. 29 Zhang H-T, Harris AL. Anti-angiogenic therapies in cancer clinical trials. Exp Opin Invest Drugs 1998; 7: 1629-55
30. 30 Weidner N. Intratumoral vascularity as a prognostic factor in cancers of the urogenital tract. Eur J Cancer 1996; 32A: 2506-12
31. 31 Bostwick DG, Wheeler TM, Blute M et al. Optimised microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996; 48: 47-57
32. 32 Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994; 73: 678-87
33. 33 Olivarez D, Ulbright T, Deriese W et al. Neovascularization in clinical stage A testicular germ cell tumour: prediction of metastatic disease. Cancer Res 1994; 54: 2800-2
34. 34 Viglietto G, Romano A, Maglione D et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 1996; 13: 577-87
35. 35 Fukuda S, Shirahama T, Imazono Y et al. Overexpression of vascular endothelial growth factor (VEGF) in testicular germ cell tumours as an indicator of metastatic disease. J Urol 1998; 159: 48
36. 36 Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32A: 2534-9
37. 37 Jeltsch M, Kaipainen A, Joukov V et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997; 276: 1423-5
38. 38 Jain R. Delivery of novel therapeutic agents in tumours. Physiological barriers and strategies. J Natl Cancer Inst 1989; 81: 570-6
39. 39 Salven P, Lymboussaki A, Heikkila P et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumours. Am J Path 1998; 153: 103-8